Saturday, October 31, 2026

GBP/EUR Bullish Momentum With A 1% Rise In The Last 5 Sessions

ViaNews Editorial Team

February 14, 2023

GBP/EUR Bullish Momentum With A 1% Rise In The Last 5 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 1.18% for the last 5 sessions. At 09:06 EST on Tuesday, 14 February, GBP/EUR (GBPEUR) is $1.13.

GBP/EUR's yearly highs and lows, it's 4.874% up from its 52-week low and 6.958% down from its 52-week high.

Volatility

GBP/EUR's last week, last month's, and last quarter's current intraday variation average was a positive 0.17%, a negative 0.01%, and a positive 0.32%, respectively.

GBP/EUR's highest amplitude of average volatility was 0.17% (last week), 0.36% (last month), and 0.32% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GBP/EUR's Forex is considered to be oversold (<=20).

News about

  • Usd/jpy forex signal: to retest 134.76 if this happens - 14 February 2023. According to DailyForex on Tuesday, 14 February, "The USD/JPY pair initially slumped to a low of 129.76 on Friday and then pared back those losses to about 132.85.", "Therefore, the USD/JPY pulled back after media reports said that the next governor will be Kazuo Uoda, a macroeconomics expert. "
  • Usd/jpy price analysis: ascending triangle, double tops tease bears around 132.00. According to FXStreet on Tuesday, 14 February, "Also justifying the USD/JPY pair's latest weakness is the RSI (14) line that took a U-turn from the overbought conditions, not to forget the bearish MACD signals.", "In a case where the USD/JPY drops below 130.30, the 130.00 round figure may act as a validation point for the quote's further downside."
  • Usd/jpy Marches beyond 132.00 as boj policy appears safe, Japan gdp, US inflation eyed. According to FXStreet on Monday, 13 February, "Moving ahead, the preliminary readings of Japan's fourth quarter (Q4) Gross Domestic Product, up for publishing on Tuesday, will precede the Japanese policymakers' official selection of the BoJ leaders to direct short-term USD/JPY moves. ", "Elsewhere, the mildly hawkish Fed talks join Friday's strong US Consumer Sentiment and US inflation expectations to offer extra strength to the USD/JPY prices, via US Dollar strength. "
  • Usd/jpy tracks downbeat yields, hawkish boj concerns near 132.00, focus on US inflation. According to FXStreet on Tuesday, 14 February, "Following that, the official nomination of Kazuo Ueda as the BoJ leader weighed on the USD/JPY prices. ", "Moving on, the market consensus anticipates 6.2% YoY print of the US CPI for January but the odds of the positive surprise during the year-start are high, which in turn keeps USD/JPY bears on the dicey floor."

More news about GBP/EUR (GBPEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com